Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rapport Therapeutics, Inc.

NASDAQ: RAPP · Life Sciences · 15 alerts · CIK 2012593

Share price
$24.82Close, Nov 16
Market cap
$1.47B
Shares outstanding
59.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rapport Therapeutics, Inc. filings on SEC EDGAR ↗

7:31 AM ET 10-Q
Financial Results

Rapport Therapeutics Q3 2026 Results: Net Loss of $40.2M, Loss Widens

Rapport Therapeutics is a clinical-stage biotechnology company that has incurred significant financial losses since inception and expects to continue doing so. As of November 2, 2026, the company had 59,279,630 shares of common stock outstanding and is focused on developing its lead product candidate, RAP-219, for neurological disorders.

Key figure
Net loss $40.2M
7:13 AM ET 8-K
Financial Results

Rapport Therapeutics Financial Results

Rapport Therapeutics reported third quarter 2026 financial results and highlighted positive Phase 2 topline results for RAP-219 in bipolar mania. The company is well-capitalized with $815.4 million in cash following a recent financing, providing a projected runway through the end of 2029.

Term
Q3 2026

“Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company. RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets.”

Abraham N. Ceesay, chief executive officer of Rapport
7:33 PM ET Form 4
Insider Buying

Rapport Therapeutics Insider James Healy Buys $20.4M of Stock

James Healy bought 969,480 shares of Rapport Therapeutics, Inc. at $21.00 a share, worth $20.4M in total on Oct 28, 2026. Shares held after the trade: 25,267 (+37.8%).

Value
$20.4M
Shares
969,480
Average price
$21.00
Holding change
+37.8%
Trade date
Oct 28, 2026
5:13 PM ET 8-K
Capital Raise

Rapport Therapeutics Capital Raise of $216M

Rapport Therapeutics entered into an underwriting agreement for a public offering of 8,333,334 shares of common stock and 1,190,476 pre-funded warrants at a price of $21.00 per share. The underwriters fully exercised their option to purchase an additional 1,428,571 shares, bringing estimated net proceeds to approximately $215.7 million. The funds are intended to support clinical trials for RAP-219 and other research and development activities.

Value
$216M
Counterparty
Morgan Stanley & Co. LLC
4:30 PM ET Form 4
Insider Selling

Rapport Therapeutics CEO Abraham Ceesay Sells $64.4K of Stock

Abraham Ceesay, CEO, sold 2,210 shares of Rapport Therapeutics, Inc. at $29.16 a share, worth $64.4K in total on Oct 21, 2026. Shares held after the trade: 450,035 (-0.5%).

Value
$64.4K
Shares
2,210
Price
$29.16
Role
CEO
Holding change
-0.5%
Trade date
Oct 21, 2026
4:01 PM ET Form 4
Insider Buying

Rapport Therapeutics Director Ramiro Sanchez Buys $98.5K of Stock

Ramiro Sanchez, Director, bought 3,600 shares of Rapport Therapeutics, Inc. at $27.35 a share, worth $98.5K in total on Oct 23, 2026. Shares held after the trade: 3,600.

Value
$98.5K
Shares
3,600
Price
$27.35
Role
Director
Trade date
Oct 23, 2026
4:57 PM ET Form 4
Insider Buying

Rapport Therapeutics Director Paul M. Silva Buys $99.6K of Stock

Paul M. Silva, Director, bought 3,680 shares of Rapport Therapeutics, Inc. at $27.07 a share, worth $99.6K in total on Oct 22, 2026. Shares held after the trade: 3,680.

Value
$99.6K
Shares
3,680
Price
$27.07
Role
Director
Trade date
Oct 22, 2026
4:57 PM ET Form 4
Insider Buying

Rapport Therapeutics Director Wendy B. Young Buys $100K of Stock

Wendy B. Young, Director, bought 3,789 shares of Rapport Therapeutics, Inc. at $26.39 a share, worth $100K in total on Oct 22, 2026. Shares held after the trade: 13,289 (+39.9%).

Value
$100K
Shares
3,789
Price
$26.39
Role
Director
Holding change
+39.9%
Trade date
Oct 22, 2026
4:57 PM ET Form 4
Insider Buying

Rapport Therapeutics Director Steven M. Paul Buys $974K of Stock

Steven M. Paul, Director, bought 35,714 shares of Rapport Therapeutics, Inc. at $27.28 a share, worth $974K in total on Oct 22, 2026. Shares held after the trade: 77,380 (+85.7%).

Value
$974K
Shares
35,714
Price
$27.28
Role
Director
Holding change
+85.7%
Trade date
Oct 22, 2026
4:56 PM ET Form 4
Insider Buying

Rapport Therapeutics Director John Maraganore Buys $249K of Stock

John Maraganore, Director, bought 9,411 shares of Rapport Therapeutics, Inc. at $26.38 to $26.92 a share (average $26.45) in 2 transactions, worth $249K in total on Oct 22, 2026. Shares held after the trade: 9,411 (+14.2%).

Value
$249K
Shares
9,411
Average price
$26.45
Role
Director
Holding change
+14.2%
Trade date
Oct 22, 2026
5:47 PM ET Form 4
Insider Buying

Rapport Therapeutics CFO Troy A. Ignelzi Buys $144K of Stock

Troy A. Ignelzi, CFO, bought 5,500 shares of Rapport Therapeutics, Inc. at $26.10 a share, worth $144K in total on Oct 21, 2026. Shares held after the trade: 15,500 (+55.0%).

Value
$144K
Shares
5,500
Price
$26.10
Role
CFO
Holding change
+55.0%
Trade date
Oct 21, 2026
6:06 AM ET 8-K
Clinical Trial Data

Rapport Therapeutics Clinical Trial Data

Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania, meeting the primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in the YMRS total score. The drug was well-tolerated with no serious adverse events, establishing clinical proof-of-concept for its novel TARP g8-selective mechanism. The company plans to progress RAP-219 into Phase 3 trials for bipolar mania in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.